2015
DOI: 10.1007/s12288-015-0558-6
|View full text |Cite
|
Sign up to set email alerts
|

Clinicopathological Analysis of B Cell Lymphomas, Unclassifiable; with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma in a Tertiary Care Hospital in Southern India

Abstract: (2008) to overcome the problems of difficulty in classifying certain lymphomas having overlapping morphological, immunophenotypical and genetic features. To study the clinicopathological profile of BCLu-DLBCL/BL. Crosssectional study over 3 year period in the Haematology section of Department of Pathology in a large teaching hospital in Southern India from January 2011 to December 2013. All the cases reported as BCLu-DLBCL/BL were collected and the clinical, morphological and immunohistochemical parameters we… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2017
2017
2017
2017

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 21 publications
(20 reference statements)
0
1
0
Order By: Relevance
“…However, several studies have reported that GZL may also present at extramediastinal sites. [ 2 , 6 8 ] Owing to the relative rarity of these lymphomas, a consensus on the appropriate therapeutic approach is yet to be achieved. Current treatment approach is based on doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), while that for CHL and DLBCL requires addition of rituximab, based on CD20 expression of the neoplastic cells.…”
Section: Introductionmentioning
confidence: 99%
“…However, several studies have reported that GZL may also present at extramediastinal sites. [ 2 , 6 8 ] Owing to the relative rarity of these lymphomas, a consensus on the appropriate therapeutic approach is yet to be achieved. Current treatment approach is based on doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), while that for CHL and DLBCL requires addition of rituximab, based on CD20 expression of the neoplastic cells.…”
Section: Introductionmentioning
confidence: 99%